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Introduction
Dendritic cells (DCs) play critical roles in immune defense 
development, due to their highly diverse endocytic networks,1–4 
promoting adaptive immune responses.4–8 Yet DCs show lim-
ited intracellular uptake of nucleic acids.4 Synthetic nanopar-
ticulate delivery has shown promise for facilitating intracellular 
uptake of RNA molecules,4,9–14 proving particularly useful for 
delivering oligoRNA such as siRNA. Nevertheless, this does 
not guarantee similar success with the more complex self-
replicating (self-amplifying) replicon RNA (RepRNA). Its size 
being over 100 kb, compared with the tens of bases for oli-
goRNAs, will influence the interaction with synthetic nanopar-
ticulate delivery vehicles; there will also be fewer molecules 
of RepRNA per nanoparticle. More importantly are the dif-
ferent intracellular sites to be targeted for functional readout. 
RepRNA must translate by interacting with the ribosomal 
machinery, unlike siRNA, which interacts with RNA interfer-
ence pathway components. Both the translation and subse-
quent replication of RepRNA render it particularly sensitive 
to RNase, which can easily destroy ribosomal entry or gene 
translation. The latter is especially problematic for RepRNA 
translating as a polyprotein.
RepRNA offers the capacity for gene delivery, including 
genes encoding vaccine antigens such as those of influ-
enza virus.4,14–18 Both the number of mRNA molecules and 
the half-life of translation are enhanced through delivery of 
RepRNA.4,14 This is due to RepRNAs behaving like viruses; 
they are defective virus genomes—essential genes encoding 
viral structural proteins are deleted—which still translate 
and replicate without producing progeny virus.4,14–20 Thus, 
RepRNA provides the template for increasing the number 
of RNA molecules translating, which in turn increases the 
rounds of antigen production.
RepRNA delivery has focused on virus replicon particles 
(VRPs),15–17,19,20 but VRP delivery is dependent on the cell 
tropism of the particle, which is not readily modified for con-
trollable targeting of DCs. VRPs also suffer from species or 
individual restriction for infecting cells, while anti-VRP host 
immunity can prevent delivery. Electroporation of replicons has 
been reported,21 but again does not guarantee DC targeting.
We therefore sought to determine if synthetic nanoparticu-
late vehicles could promote RepRNA delivery to DCs, due 
to their application with mRNA.4,11,13 Our approach adapted 
a process for synthetic, particulate vehicle delivery to the 
RepRNA.14 The aim was to define RepRNA delivery to DCs 
promoting RNA translocation from endocytic vesicles into the 
cytosol for translation. This is an important consequence con-
sidering that DCs possess the major capacity to process and 
present translated antigens,22 leading to activation of immune 
defense.4–8 DCs also transport antigen into lymphoid tissues 
and organs;4,23 properties epithelial cells do not possess. 
Importantly, the DCs must survive RepRNA delivery. This 
requires application of noncytopathogenic RepRNA14,22,24 
rather than the frequently employed cytopathogenic alpha-
virus replicons—noncytopathogenic RepRNA permits pro-
longed retention of the RNA and translated antigens for 
interaction with the immune system.4,7
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Self-amplifying replicon RNA (RepRNA) possesses high potential for increasing antigen load within dendritic cells (DCs). The 
major aim of the present work was to define how RepRNA delivered by biodegradable, chitosan-based nanoparticulate delivery 
vehicles (nanogel-alginate (NGA)) interacts with DCs, and whether this could lead to translation of the RepRNA in the DCs. 
Although studies employed virus replicon particles (VRPs), there are no reports on biodegradable, nanoparticulate vehicle 
delivery of RepRNA. VRP studies employed cytopathogenic agents, contrary to DC requirements—slow processing and antigen 
retention. We employed noncytopathogenic RepRNA with NGA, demonstrating for the first time the efficiency of RepRNA 
association with nanoparticles, NGA delivery to DCs, and RepRNA internalization by DCs. RepRNA accumulated in vesicular 
structures, with patterns typifying cytosolic release. This promoted RepRNA translation, in vitro and in vivo. Delivery and 
translation were RepRNA concentration-dependent, occurring in a kinetic manner. Including cationic lipids with chitosan during 
nanoparticle formation enhanced delivery and translation kinetics, but was not required for translation of immunogenic levels 
in vivo. This work describes for the first time the characteristics associated with chitosan-nanoparticle delivery of self-amplifying 
RepRNA to DCs, leading to translation of encoded foreign genes, namely influenza virus hemagglutinin and nucleoprotein.
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Accordingly, our major aim was to define how RepRNA 
delivered by chitosan-based delivery vehicles  (nanogel- 
alginate (NGA)) interact with DCs. This is the first descrip-
tion of RepRNA delivery to DCs by synthetic nanoparticu-
late vehicles, which provided both RNase protection and 
delivery. The outer alginate coat of these vehicles promoted 
interaction with the DCs, but it was not essential—this was 
also noted with the chitosan core lacking an alginate coat. 
Cytosolic translocation was likely dependent on this cationic 
chitosan core, for which the additional presence of cationic 
lipids proved advantageous with low RNA concentrations. A 
major aim of the study was to characterize DC handling of 
nanoparticle-delivered RepRNA, relating this ultimately to 
RepRNA translation. Analyses were primarily in vitro, to facili-
tate detailed study of the DCs and RNA translation, which 
is difficult to monitor directly in vivo. Nevertheless, it was 
considered important to confirm that the in vitro data were 
pertinent, for which reason in vivo studies were performed to 
confirm that translation of nanogel-delivered RepRNA was 
not simply an in vitro phenomenon.
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Results
NGA-RepRNA complexes
It was important to ascertain that RepRNA efficiently interacted 
with the chitosan during NGA formation. The ΔErns replicon con-
struct (Figure 1a) was labeled with fluorescein isothiocyanate 
(FITC) for this purpose. Flow cytometry forward and side scat-
ter settings were adjusted to detect the particular light scatter-
ing properties of the NGA (Figure 1b, NGA alone). This was 
not an attempt to define size, but simply visualize the particles, 
which were clearly distinguishable from diluent alone (MQ-
water) (Figure 1b). Dy490-labeled RepRNA alone (Figure 1b; 
Replicon alone) provided a clear shift in FL-1, but no change 
in side (or forward) scatter profiles over diluent alone. When 
RepRNA was incorporated with chitosan during NGA forma-
tion, the RepRNA fluorescence signal clearly associated with 
the particles (Figure 1b; NGA (2 μg RNA) to NGA (16 μg RNA)).
The influence of RepRNA on NGA size and ζ-potential was 
assessed, in comparison with oligoRNA. These were deter-
mined in water and Dulbecco's modified Eagle's medium 
(DMEM), the latter being more pertinent to interaction with 
DCs. Suspension in DMEM did modify the image of NGA 
obtained in water, as already reported25 (Figure 1c). In 
DMEM, RepRNA slightly increased particle dHZ and polydis-
persity index (PDI), while oligoRNA had little or variable effect. 
ζ-potential was unaffected by RepRNA, while oligoRNA led 
to a more negative ζ-potential.
Chitosan also protected labeled RNA probes against 
RNase (Figure 1d). This was confirmed with gel analysis of 
RNA integrity (Figure 1e). It was not possible to employ NGA 
due to the damage to the RNA cargo when attempting to 
release it for analysis, but the properties of chitosan were 
expected to be reflected in the NGA.
NGA-mediated delivery of RNA to DCs
Initial characterizations using fluorochrome-labeled oli-
goRNA (Dy781-O1-RNA) probes showed that RNA alone 
did not associate with DCs, but required NGA delivery 
(Figure 2a); lipofectamine served as a transfection control. 
NGA delivery to monocyte-derived DCs (MoDCs) was in a 
kinetic manner (Figure 2a). Variation in the signal showing 
delivery varied between experiments (Figure 2a compared 
with Figure 2b); this was noted using DCs prepared on differ-
ent days from the same animals as well as cells from different 
blood donors (data not shown). Analyzing whole cell pellets 
in place of cell lysates improved visualization of delivery, 
particularly at later time points (Figure 2b), confirming the 
kinetic nature over a 24-hour period.
Modified NGA interaction with DCs
Lipofectamine 2000 (Lipo) was employed as a positive trans-
fection control, but was also tested for its influence when 
incorporated together with chitosan during NGA formation 
(NGA-Lipo). Due to their more cationic nature, chitosan cores 
(without the alginate coating) were also assessed. Using 
labeled chitosan, NGA delivery was frequently observed as 
a vesicular distribution in MoDCs (Figure 2c). NGA-Lipo for-
mulations, and particularly chitosan cores, aggregated upon 
interaction with MoDCs (Figure 2c), which proved somewhat 
detrimental to DC integrity for the cores, but not NGA-Lipo. 
Nevertheless, cells were observed at 16 hours with discrete 
vesicular inclusions, similar to those obtained with the NGA 
delivery.
Use of Dy781-O1-RNA cargoes confirmed that NGA, NGA-
Lipo, and chitosan cores would deliver to MoDCs  (Figures 2d). 
A more rapid delivery was apparent with the NGA-Lipo 
(observed after 1–2 hours), but by 16–24 hours, all three 
delivery systems provided similar results.
Comparative delivery of oligoRNA and RepRNA
NGA delivery of oligoRNA and RepRNA was compared using 
MoDCs and blood DCs. The latter offered additional informa-
tion from the intensity of CD172a expressions—CD172ahi 
cells are dominated by monocytes, CD172alo cells are dom-
inated by DCs,26,27 although DC subsets are found in both 
populations. Within 1 hour, similar percentages of the cells 
were positive for NGA-delivered RepRNA and oligoRNA 
(Figure 3a). Both CD172ahi and CD172alo cells were positive 
for RepRNA, whereas oligoRNA was primarily with CD172ahi 
cells. By 16 hours, the RepRNA distribution in both CD172ahi 
and CD172alo cells was confirmed, while oligoRNA remained 
with the CD172ahi population. Moreover, the percentage of 
oligoRNA+ cells was similar at 1 and 16 hours, whereas the 
percentage of RepRNA+ cells doubled, and the relative fluo-
rescence signal increased (Figure 3a).
Modified NGA delivery efficiency for RepRNA
NGA were prepared with 4 μg as well as the 2 μg FITC-
labeled RepRNA most often used, to facilitate addition of 
different amounts of NGA-associated RepRNA to a fixed 
number (2 × 105) of CD172a+ cells (Figure 3b). Detectable 
Figure 1  Replicon constructs and replicon interaction with chitosan. (a) Gene arrangement of the classical swine fever virus (CSFV) 
genome parent for the replicon RNA (RepRNA) constructs (CSFV parent), showing the Erns gene deletion for the ΔErns replicon. Insertion of 
the influenza virus hemagglutinin (HA) and nucleoprotein (NP) genes at the 3′ end of the Npro gene are shown as HA replicon and NP replicon 
(the luciferase RepRNA has the luciferase gene inserted at the same position). Insertion of the influenza virus HA at the 3′ end of the C gene 
is shown as C-HA-C replicon. The inserted EMCV IRES ensured reinitiation of translation of the RepRNA after the inserted influenza virus 
genes. (b) Encapsulation efficiency for RepRNA interacting with chitosan during the formation of the chitosan cores of the nanoparticles. The 
RepRNA was labeled with FITC. Chitosan-based nanoparticles (NGA) are detected by their side scatter (or forward scatter, data not shown) 
profiles in the Flow Cytometer; RepRNA is detected in the FL-1 channel. The signal level with diluent alone (MQ-water) or NGA alone set the 
gating for positive FL-1 signals. Different concentrations of RepRNA were associated with the NGA (from 2 to 16 μg RepRNA in 17 μl 0.1% 
TPP plus 250 μl chitosan, made up to 1 ml prior to analysis). (c) Physical characteristics of the NGA, alone or carrying oligoRNA or RepRNA 
cargoes, measured in water (the standard diluent for NGA production) or in Dulbecco's modified Eagle's medium (DMEM) (the medium 
in which the NGA were employed for interaction with dendritic cells (DCs)). Measurement of the hydrodynamic diameter (Z-average size, 
dHZ), polydispersity index (PDI) and surface charge (ζ-potential) was by dynamic light scattering at 25 °C with a scattering angle of 173°. (d) 
Capacity of chitosan to protect fluorochrome-labeled RNA probes from RNAse-dependent release of the fluorochrome, using the RNaseAlert 
Kit. Interaction of chitosan with the RNA in either water or Tris buffer was compared with RNA alone (in Tris buffer is shown; in water gave the 
same results) and RNA with TPP in water or Tris buffer. (e) Influence of chitosan on protecting the integrity of a Dy-781 labeled 50-mer RNA 
probe against RNase digestion, using the procedure described by Python et al.49 TPP, tripolyphosphate.
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RepRNA+ cells increased in a RepRNA concentration-
dependent manner, with maximum levels observed using 
4 μg RepRNA. This concentration-dependent delivery 
appeared to be saturable, but there was a distribution shift 
with the higher concentrations of RepRNA associating with 
CD172alo cells more than the lower concentrations.
Figure 2 Chitosan-based nanoparticle delivery to dendritic cells (DCs). The results shown are representative of 3 (microscopy) and 5–10 
(RNA blots) individual experiments. (a) Left blot: NGA delivery of a Dy781-labeled oligoRNA probe to MoDCs in comparison with lipofectamine 
2000 transfection and RNA alone—RNA measured in cell lysates from MoDCs treated with the NGA for different periods of time. Right blot: 
Similar to the left blot, but comparing cell lysates with supernatant medium from cells before lysis—kinetics of RNA association with MoDCs; 
lipofectamine and electroporation are used as transfection controls. (b) As in (a), but comparing the signal obtained from lysates with cell 
pellets prior to lysis. (c) Uptake of chitosan-based nanoparticles and delivered RNA by DCs. NGA interaction with MoDCs at 2 and 16 hours 
was observed by confocal microscopy using rhodamine labeled chitosan for generating the NGA. The pattern of interaction with the DCs is 
compared with that obtained using the chitosan cores of NGA (no alginate coating) and NGA-Lipo, in which lipofectamine 2000 was mixed with 
the chitosan prior to addition of the TPP to form the cores of the nanoparticles. The scale bar is 20 or 10 μm with the extreme right image in 
each row. (d) Comparison of NGA with chitosan cores and NGA-Lipo for the kinetics of RNA delivery to MoDCs, using the same experimental 
conditions for (b), except only cell pellet analysis is shown.
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NGA-Lipo formulations were compared with NGA for 
Dy490-UTP-labeled RepRNA delivery, again using CD172a+ 
blood cells. Although RNA delivery was enhanced by NGA-
Lipo (as observed with oligoRNA delivery; Figure 2d), this was 
most obvious when the NGA delivery level was low (0.2 μg/
RepRNA; Figure 4a). This was not due to the presence of 
free Lipo in the preparations—Lipo alone has higher dHZ 
than NGA-Lipo, and positive rather than negative ζ-potential 
 (Figure 4b). Moreover, association of Lipo in the NGA for-
mulation only slightly increased dHZ with no influence on PDI 
or ζ-potential in DMEM (Figure 4b). The added presence of 
RepRNA did render a less negative ζ-potential on the NGA-
Lipo, and also reduced the dHZ and PDI (Figure 4b).
Intracellular RepRNA delivery
RepRNA translation requires cytosolic translocation follow-
ing delivery to cells. Consequently, the CD172a-labeling was 
employed as a DC surface indicator to characterize intracellu-
lar uptake of NGA-delivered RepRNA. Within 1 hour at 39 °C, 
the RepRNA signal (red) was observed on the cytosolic side 
of the CD172a-labeled surface (blue) (Figure 5a). This con-
trasted with incubation at 4 °C—RepRNA remained closely 
Figure 3 Comparative delivery of replicon RNA (RepRNA) and oligoRNA to CD172a+ blood cells (monocytes plus dendritic cells 
(DCs)). The results shown are representative of three individual experiments. (a) NGA delivery of Dy490-RepRNA or Alexa488-oligoRNA to 
CD172a+ cells (4 μg/ml RNA prepared as in Figure 1b and 2a in Dulbecco's modified Eagle's medium (DMEM), added directly to the cells) 
after 1 or 16 hours incubation at 39 °C in DMEM supplemented with 10% (v/v) porcine serum to maintain cell viability. The y-axis shows the 
intensity of the labeled RNA signal, while the x-axis shows the intensity of the CD172a labeling (the blood DCs are mostly present in the 
CD172alo population, but the conditions to maintain cell viability will permit the monocytes to begin differentiation). The gated population 
shows the RNA+ cells, based on a negative gate created with the negative (NGA alone) sample. (b) As in (a), using different concentrations 
of fluorescein (FITC)-labeled RepRNA delivered to the cells by NGA as in  Figure 1b, prepared in DMEM; the amount of RepRNA shown is 
the concentration per milliliter when added to the cells.
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associated with the CD172a-labeled surface (Figure 5a). 
The confocal microscopy also showed stronger signals and 
more positive cells for RepRNA than oligoRNA (Figure 5a), 
and the RepRNA signal increased from 1 to 18 hours.
Imaris software Surface Module was employed to enhance 
the CD172a-defined cell surfaces, to confirm the intracellular 
localization of delivered RNA (Figure 5b). The bright (red) 
staining was reminiscent of vesicular structures, but the form 
and edges of those with RepRNA were not so readily dis-
cernible, often “coalescing”. Moreover, an additional more dif-
fuse (and weaker) staining pattern of RepRNA was observed, 
closely associated with the more densely staining structures, 
reminiscent of cytosolic translocation events.28,29 Accordingly, 
images were acquired by scanning through a larger depth of 
the cell (Figure 5c). These experiments also compared NGA 
and NGA-Lipo delivery (0.2 μg/RepRNA to facilitate obser-
vation of NGA-Lipo enhanced delivery). RepRNA+ inclusions 
(green) together with associated diffuse staining were again 
observed (Figure 5c). These events were most numerous 
and visible with the NGA-Lipo delivery of 0.2 μg/RepRNA 
(Figure 5c).
DC detection of and response to NGA formulations
Considering that DCs were capable of both interacting with 
and internalizing NGA carrying RepRNA, analyses were 
performed to determine if the cells were capable of detect-
ing the presence of the NGA. The DCs showed no apparent 
modulation in the presence of RepRNA free of any particu-
late formulation (data not shown); nor did the cells respond to 
that RNA, which reflects their poor capacity for internalizing 
free RepRNA. Accordingly, migration assays were performed 
as described in Materials and Methods to determine if DCs 
actually detect the presence of the chitosan nanoparticulate 
vehicles. In order to prevent random interaction between the 
cells and the particles, NGA and DC were separated by tran-
swell filters; only the cells that traversed the filters into the 
NGA-containing compartment were measured. The results 
(Figure 6a) are shown as the number of cells migrating and 
the migration index (number of cells migrating to the NGA for-
mulations relative to the medium control—random migration). 
Both the complete CD172+ cell population (monocytes plus 
DCs) and the CD14− subset (CD14− DCs) migrated toward 
the NGA formulations. This was often more prominent than 
migration toward the LPS ligand for TLR4 serving as a posi-
tive control. The additional presence of the RepRNA (NGA 
RepRNA) or RepRNA and cationic lipid (NGA-Lipo RepRNA) 
in the nanoparticle structure did not interfere with the migra-
tion characteristics.
In contrast to this apparent ability of the DCs (and mono-
cytes) to detect the presence of the NGA formulations, there 
was no detectable activation of the cells. This was monitored 
in terms of flow cytometric forward and side scatter proper-
ties (FSC versus SSC; Figure 6b), as well as NFκB nuclear 
translocation and IL-6 induction (data not shown).
Figure 4 Influence of cationic lipid molecules on NGA delivery of RNA related to the NGA characteristics. (a) As in Figure 3a, but 
showing the enhanced level of Dy-490 labeled replicon RNA (RepRNA) delivery after 1 hour at 39 °C offered by NGA-Lipo when NGA delivery 
provides a low percentage of RNA+ cells (2 μg/ml RepRNA prepared as in  Figure 1b, diluted 1:10 to have 0.2 μg/ml when added to the cells). 
(b) As in  Figure 1c, but comparing NGA and NGA-Lipo carrying RepRNA, as well as Lipofectamine 2000 alone.
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Figure 5 Intracellular delivery of replicon RNA (RepRNA) and oligoRNA by NGA and NGA-Lipo. (a) Confocal microscopy images from 
3D scans of narrow sections through the centre of blood CD172a+ cells. NGA was used to deliver rhodamine-labeled RepRNA or Alexa488-
labeled oligoRNA, prepared as in  Figure 1b to give 2 μg/ml when added to the cells; incubations were 1 hour at 4 °C or 1 and 18 hours at 
39 °C as shown. The cell surface was labeled with anti-CD172a antibody. Cell surface labeling is colored turquoise, while the RNA signal is 
colored red, to facilitate comparative observations. All micrographs are 3D Blend images with threshold subtraction and gamma correction 
set as in the “Cells alone” control; the 3D mages have been turned to provide a comparative view through the cells. Scale bars are all 5 μm. 
(b) As in (a), for 18 hours at 39 °C, but showing a zoom together with resolution format to provide optimum voxel sizes for the fluorochromes 
employed. maximum intensity projection and Blend versions of the 3D images are provided for both RepRNA and oligoRNA delivery observed 
after 18 hours incubation. In the Blend 3D images, the surface module of the Imaris software was employed with the CD172a labeling to create 
an enhanced depiction of the cell surface in this narrow section through the centre of the cells. Scale bars are 2 μm. (c) Similar to (b) 18 hours 
at 39 °C, but using 0.2 μg RepRNA/ml when added to the cells, with which NGA delivery was weak; this allowed observation of an enhanced 
delivery by NGA-Lipo. In this experiment, the cell surface is colored red, while the RepRNA is green. Again, all settings are from those set with 
the Cells alone control, and the surface labeling was enhanced using the surface module of the Imaris software. The scale bars are 3 μm for 
“cells alone”, 2 μm for “NGA-RNA” with 15 μm for the insert, and 1.5 μm for “NGA-Lipo-RNA” with 10 μm for the insert.
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Translation of delivered RepRNA in vitro
With the images in Figure 5 suggesting cytosolic 
 translocation,28,29 essential for RepRNA translation, nanopar-
ticle delivery of RepRNA encoding luciferase (RepLuc) was 
assessed. For these analyses, a delivery of 0.2 μg RepRNA 
was again employed, to facilitate detection of enhanced 
delivery by NGA-Lipo particles (see Figures 4a and 5c).
Not unexpectedly, VRP delivery to MoDCs provided the 
strongest luciferase signal (Figure 7a)—VRPs, like the virus, 
target DCs for replication.22 Analysis of early kinetics showed 
that NGA-Lipo and chitosan core formulations provided a 
24-hour readout in MoDCs, yielding similar luciferase transla-
tion kinetics from as early as 2 hours postdelivery (Figure 7a, 
left graph). These luciferase levels continued to increase by 
24 hours (Figure 7a, left graph), although not surprisingly 
they did not reach those obtained with VRPs. NGA deliv-
ery with this low 0.2 μg RepRNA did not provide luciferase 
readout within 24 hours, in agreement with the poor sig-
nals obtained with labeled RNA (0.2 μg RepRNA) delivery 
(Figures 3b and 4a).
Looking beyond 24 hours to determine durability of transla-
tion, indicative of replication (Sutter et al., personal communi-
cation), VRPs again provided the strongest signal, maintained 
over 96 hours as evidence of replication (Figure 7a, 
right histogram). Lipofection gave lower and variable (among 
experiments) readouts (data not shown), which were not 
maintained over 96 hours (Figure 7a, right histogram). NGA 
delivery was more consistent than lipofection across experi-
ments (data not shown); a readout was noted at 48 hours and 
maintained at 96 hours (Figure 7a, right histogram). NGA-
Lipo delivery yielded clear luciferase signals from 24 hours, 
as noted for the early kinetics; these were also maintained 
over 96 hours (Figure 7a, right histogram). Interestingly, 
chitosan core delivery again provided moderate luciferase 
readouts, from 24 hours (Figure 7a; no 96 hours sample was 
available due to core-induced cell damage).
RepRNA delivery was also assessed for translation of the 
NS3 viral protein necessary for RepRNA replication. Both 
MoDCs and blood-derived DC/monocytes were employed—
Figure 7b shows results with blood cells. NGA delivery 
yielded an NS3 readout; in agreement with the results on 
RNA delivery (Figure 3b), this was dependent on the con-
centration of RNA delivered. The 0.2 μg/ml again did not 
provide a detectable readout; efficiency of translation was 
discernible in a concentration-dependent manner from 0.4 
μg/ml, reaching maximum at 2–8 μg/ml delivered RepRNA. 
The NS3 translation from NGA-delivered RepRNA was on a 
par to that for VRP when high levels of RepRNA were deliv-
ered, but more efficient than lipofection.
Translation of delivered RepRNA in vivo
While the in vitro data clearly demonstrated that nanoparticu-
late delivery of RepRNA to DCs led to RepRNA translation, 
it was considered important to confirm that such translation 
was pertinent within an in vivo environment. For this purpose, 
we considered that induction of antibody would prove an 
informative readout, due to the fact that the B-lymphocytes 
require intact antigen rather than processed peptides (as for 
Figure 6 Dendritic cell sensing of NGA formulations. (a) CD172a+ sorted cells (0.5 × 106 cells/well; prelabeled with anti-CD172a and anti-
CD14 antibodies) were placed in a 3 μm filter transwell inserts, and added into wells of 24-well companion plates preseeded with the NGA 
formulations (10% v/v in phenol red-free DMEM) or controls as shown on the x-axis. Following incubation at 39 °C for 3 hours, the cells which had 
migrated through the filters into the chamber containing the NGA formulations were assessed by flow cytometry. Quantification of the migrated 
cells was performed by counting a reference of 5000 CountBright beads to obtain the number of migrating cells/cm3. This was related to the 
number of migrating cells obtained with the medium control to give the migration index. (b) CD172a+ sorted cells were incubated either alone 
(“negative”), with NGA (“NGA alone”), with NGA carrying unlabeled or labeled RepRNA (“NGA-RepRNA unlabeled”; “NGA-RepRNA FITC-
labeled”), or with NGA-Lipo carrying labeled RepRNA (“NGA-Lipo RepRNA”). Following incubation in DMEM/1% (v/v) porcine serum for 2 or 
16 hours at 39 °C, the forward and side scatter profiles (FSC, SSC) of the cells was determined by flow cytometry. The results show an example 
for the 16 hours incubation time point from 10 separate experiments; similar results were obtained with the 2 hours incubation time point.
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the T lymphocytes). Moreover, it is most difficult to accurately 
detect RepRNA translation directly in DCs in vivo, possibly 
due to the low numbers of DCs involved. Induction of anti-
body provided the more demanding test for the RepRNA, 
reflecting that the RNA did indeed successfully translate its 
encoded foreign genes as intact antigen, which in turn was 
released to interact with the B-lymphocytes. Thus, the in vivo 
analyses focused on antibody induction (Figure 8a).
This confirmation of the in vitro translation was assessed 
in vivo by injecting both mice and rabbits with RepRNA encod-
ing influenza virus hemagglutinin (HA) (H5) or nucleoprotein 
(NP) (Figure 1; “HA replicon”, “NP replicon”). Comparators 
were truly “naked” RepRNA and VRPs carrying the same 
replicon. The “naked” RepRNA never provided any readout, 
as exemplified in Figure 8a (left panel, “Rep”). VRPs induced 
anti-HA and anti-NP responses in both species (Figure 8a, 
left panel, “VRP”). NGA delivery in mice provided no anti-
HA response, but a strong anti-NP response, while in rabbits 
NGA delivered RepRNA induced both anti-HA and anti-NP 
antibodies (Figure 8a, left panel, “NGA”). Overall, anti-NP 
responses were stronger than anti-HA, relating to in vitro lev-
els of HA and NP translation by these HA-RepRNA and NP-
RepRNA (Suter et al, unpublished data).
The HA gene of the HA-RepRNA (Figure 1, “HA replicon”) 
was inserted at the same position as the NP gene. Modified 
insertion of the HA gene to be downstream of the C gene 
 (Figure 1, “C-HA-C replicon”) was found to give better trans-
lation of the HA in vitro (Suter et al, unpublished data). Thus, 
the in vivo translation experiments were repeated using this 
C-HA-C RepRNA. In addition, due to the results seen in 
 Figure 7a, NGA delivery of 0.2-μg RepRNA was compared 
with chitosan cores and NGA-Lipo. Now, NGA delivery led 
to both anti-HA and anti-NP responses in mice and rabbits 
 (Figure 8a, second panel “NGA RepRNA”). The RepRNA 
translation was able to induce responses within 7 days, which 
clearly benefited from a second injection for translation in 
vivo. With the exception of only the occasional animal, the 
titers were reasonably well clustered for each time point.
Figure 7 NGA delivers replicon RNA (RepRNA) for translation in vitro. (a) Kinetics of luciferase-encoding RepRNA (RepLuc) translation 
in MoDCs, compared with RepRNA delivered as virus replicon particles (VRPs) or transfected (lipofectamine 2000). NGA were compared with 
modified NGA (NGA-Lipo with lipofectamine 2000) and chitosan cores (no alginate coating). A final concentration of 0.2 μg RepRNA/ml added 
to the cells was employed with the NGAs; VRPs were used at three infectious VRPs per cell. Translation of the luciferase gene was determined 
during the first 24 hours (left graph) as well as after 24, 48, and 96 hours (right histogram) as described.22 A representative of five individual 
experiments is shown. (b) Concentration dependency of delivered RepRNA translation measured in terms of the replicon NS3 expression, to 
control for continued translation beyond the foreign gene insert. Similar methods to (a) were employed. NS3 expression was monitored using 
anti-NS3 monoclonal antibody, after fixing and permeabilising cells 72 hours postdelivery. NS3 detection was by flow cytometry (y-axis) with 
labeling of cell surface CD172a (x-axis) as in  Figure 3b. Positive controls were electroporation (RepRNA electro), lipofection (RepRNA lipo), 
and VRP delivery (VRP). A representative of three individual experiments is shown.
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Figure 8 NGA delivers replicon RNA (RepRNA) for translation in vivo. (a) Mice and rabbits were injected subcutaneously at 0, 14, and 
28 days as described in Materials and Methods (left panel). RepRNA (0.2 μg HA-RepRNA in 50 μl plus 0.2 μg NP-RepRNA in 50 μl) was 
delivered in NGA, and compared with the RepRNA alone (Rep) or virus replicon particles (VRP) delivery (105.7 VRP units for each RepRNA 
in 50 μl). Mice received 50 μl of each RepRNA mixed together, while rabbits received twice this dosage; all vaccines were adjuvanted in 
PEGylated MALP-2 adjuvant. Serum samples were assessed for anti-hemagglutinin (HA) and anti-nucleoprotein (NP) antibody by enzyme-
linked immunosorbent assay (ELISA) at 42 days after the first injection. Administration of NGA-RepRNA was repeated, but using the C-HA-
C-RepRNA and NP-RepRNA, as well as comparing with delivery using chitosan cores and NGA-Lipo, prepared as for (Figure 7a. Mice and 
rabbits were injected at days 0, 35, and 62 (arrows). Anti-HA and anti-NP antibody titers were estimated by ELISA at the times shown. (b) The 
immunization of mice as shown in (a) was repeated, using NGA alone, NGA-RepRNA, or NGA-Lipo-RepRNA. Splenocytes were prepared and 
used in vitro as either unstimulated controls or for restimulation with recombinant HA or NP as described in Materials and Methods. Multiple 
labeling was employed to distinguish CD4+ from CD8+ T lymphocytes gating on memory subsets, as described in Materials and Methods. 
T-lymphocyte activation was determined with respect to CD25 upregulation or reduction of the CFSE label in prelabeled cells (indicative of cell 
division). The CD25 upregulation was measured in terms of mean fluorescence intensity change, relative to that obtained with unstimulated 
splenocytes, to obtain a stimulation index (for the unstimulated splenocytes, this was set as 1). Cell proliferation was measured in terms of 
reduced CFSE signal as % cells gated as CSFElow.
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Despite the in vitro aggregation problem with chitosan 
core-RepRNA delivery, this also promoted translation in vivo 
(Figure 8a, third panel “Chitosan Cores RepRNA”), as had 
been witnessed in vitro while the cultures remained viable. 
While the titers from individuals were reasonably well clus-
tered for each time point, there was more variation for the 
anti-HA readouts.
NGA-Lipo delivery did not always display the advantages 
observed in vitro. With mice, the translation in vivo did not 
appear to be superior to that for NGA (Figure 8a, right panel 
“NGA-Lipo RepRNA”). In contrast, NGA-Lipo delivery did pro-
mote more efficient translation in rabbits, particularly notable 
early after the first injection in terms of increased titers. This 
was observed with delivery of both the C-HA-C RepRNA and 
NP-RepRNA, so was not particular to the replicon construct, 
but more to the delivery system.
In order to confirm these observations on antibody induction, 
splenocytes were taken from mice at the end of the experi-
ment to assess T-lymphocyte activity using in vitro restimulation 
with HA and NP antigen (Figure 8b). Both CD25 expression 
and reduced carboxyfluorescein diacetate succinimidyl ester 
(CFSE) signal from preloaded cells (due to cell division distrib-
uting the dye to daughter cells) were employed. Multiparameter 
flow cytometry permitted gating on CD3+ CD44high CD62Llow 
memory T-lymphocytes and CD3+, CD44low, CD62Lhigh naive 
T- lymphocytes within both the CD4+ Th-lymphocyte and CD8+ 
T
c
-lymphocyte populations. Proliferating CFSElow cells were 
scored as a percentage of the total cells within that gate. For 
cells upregulating CD25 expression, this was measured as 
mean fluorescence intensity (MFI), from which a stimulation 
index was calculated relative to the MFI obtained with unstimu-
lated cells.
Cells from certain nonvaccinated individuals have been 
found to show a degree of response (possibly aspecific or 
through naive cells) in vitro. Accordingly, the control animals 
receiving NGA alone (did not induce detectable antibody titers; 
data not shown) were employed as reference points for the 
assays—unstimulated, HA and NP restimulations (Figure 8b; 
“NGA alone”). The cells from most animals in this group did 
not respond in vitro, and the few that showed increased CD25 
expression generally gave similar responses when unstimu-
lated. Lack of HA and NP recognition was even more apparent 
with CFSE measurement—any apparent increase in CFSElow 
cells was similar to the levels obtained when unstimulated.
Splenocytes from animals receiving the NGA RepRNA 
(Figure 8b; “NGA-RepRNA”) gave clear responses to the HA 
and NP restimulation. This was most obvious with the CD25 
stimulation index. Interestingly, the CD8+ population proved to 
be the most responsive, particularly to NP restimulation. Sim-
ilar images of responsiveness to the HA and NP restimula-
tions (relative to the unstimulated cultures) were obtained with 
cells from the NGA-Lipo RepRNA-treated animals  (Figure 8b; 
“NGA-Lipo RepRNA”); the anti-NP response measured in 
terms of CFSElow cells was inferior to that observed with 
cells from the NGA RepRNA-treated animals (Figure 8b; 
“NGA RepRNA”). Nevertheless, the combined observations 
on CD25 expression and CFSElow cells confirmed that the 
T-lymphocytes in the mice had also responded to HA and 
NP antigen, which could only have arisen following RepRNA 
translation in vivo.
Discussion
Application of biodegradable, nanoparticulate delivery vehi-
cles has been widely employed with subunit and recombi-
nant antigens as well as protein-based drugs.4,30–32 However, 
such delivery is limited by the quantity of antigen or drug 
transported by the delivery vehicle, and the duration of that 
materiel within the targeted cell.4 Due to its replicative nature, 
self-amplifying RepRNA offers high potential for increasing 
antigen load within cells and maintaining prolonged antigen 
presence.4,14–17,20 Consequently, DCs would prove an impor-
tant target for RepRNA delivery.
While alphavirus replicons have been studied in depth 
during the past 20 years,15–18 most reports have employed 
cell lines. Their cytopathogenic nature is also problematic, 
precluding long-term retention of the replicon and translated 
antigen by DCs, impacting on the duration of antigen pro-
duction and immune stimulation. This presents a difficulty 
considering the characteristics of DCs—slow processing and 
retention of antigen for prolonged interaction with the adap-
tive immune system. Many of the critical issues concerning 
the manner of RepRNA delivery and interaction with DCs 
have not been answered by the most frequently employed 
mode of replicon delivery—replicons packaged as VRPs.15–
17,19,20,22,24
 This packaging requires complementing cells to 
supply the gene deleted from the replicon, but VRPs may 
preferentially target cells other than DCs. VRP application 
must also counter problems of species restriction and anti-
VRP immunity. Synthetic particulate delivery avoids such 
drawbacks associated with VRPs, offering advantages for 
RepRNA delivery.4,13,14 Application with noncytopathogenic 
RepRNA would also provide conditions more appropriate to 
DC requirements, as described in the application of synthetic 
particulate delivery vehicles for RepRNA delivery employing 
a noncytopathogenic RepRNA derived from classical swine 
fever virus.4,14
There is no direct evidence to date that synthetic, nanopar-
ticulate delivery vehicle will target large molecules such as 
RepRNA to DCs. These molecules have particular require-
ments for their delivery, leading into endocytic processes 
and routes promoting cytosolic translocation;4 only then can 
the RNA access the appropriate machinery of the cell for 
translation and replication. Such processes are unrelated 
to those required for delivery of antigen, DNA, and RNA 
interference. Accordingly, we sought to define how synthetic 
chitosan-based nanoparticle (NGA) delivery vehicles carry-
ing RepRNA interact with DCs, to ascertain the prospects 
for cytosolic delivery of self-amplifying RepRNA leading to 
translation.
An initial aim was to determine if RepRNA and chitosan-
nanoparticles were compatible. RepRNA associated effi-
ciently with NGA, the chitosan offering protection against 
RNAse. The association had little influence on the NGA phys-
ical properties. Hydrodynamic diameter, PDI, and ζ-potential 
of the NGA were measured in a physiological buffer (DMEM), 
more relevant to the physiological environments in which 
DCs would interact. The observations that the NGA char-
acteristics were different in a physiological buffer compared 
to water relates to similar observations reported by Schütz 
et al.25 This is the first description defining the interaction of 
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RepRNA with synthetic nanoparticles. Moreover, the interac-
tion did not require the addition of protein or lipids, which can 
pose problems due to their immunogenic capacities.
It was important to determine if this efficient association of 
RepRNA with NGA particles would promote interaction with 
DCs. This was essential; free RepRNA was shown in several 
experiments to be incapable of interacting directly with DCs, 
relating to similar deficiencies observed with mRNA.33–35  
RepRNA delivery unequivocally required the application 
of the NGA particles. Both the particles and the RNA car-
goes were visualized within the DCs as vesicular-like struc-
tures. Although this was considered to be a consequence of 
the high capacity for the alginate coat to interact with DCs 
(unpublished data), the alginate was not obligatory. Chitosan 
cores (no alginate coating) also interacted efficiently with 
the DCs. However, the cores showed high levels of aggrega-
tion detrimental to both uptake by the DCs and cell integrity, 
which may relate to amine protonation on chitosan requir-
ing reduced pH.36 With the cores stabilized at physiological 
pH by the alginate coating of NGA particles, this capacity 
of chitosan for amine protonation would become pertinent 
following endocytosis. As the endocytic vesicles containing 
the NGA particles interacted with endosomes, vacuolar H+-
ATPases would initiate the proton pump for acidification of 
the vesicles. Under such conditions, the amines of the chi-
tosan may become more available for protonation, which 
in turn would create a “proton sponge” effect.4,13,37,38 Such 
effects destabilize the acidifying endocytic vesicles, in turn 
facilitating cytosolic translocation of the vesicular contents, 
which is an essential step for the RepRNA to reach the site 
for translation.
In this context of NGA protonation destabilizing the endo-
cytic vesicles, we applied additional cationic components 
within the NGA structure to determine any potential benefit 
for the RepRNA delivery to DCs. Lipofectamine 2000 (Lipo) 
has been described by the manufacture as a cationic lipid-
based method for nucleic acid delivery. Accordingly, the influ-
ence of Lipo on RepRNA delivery was assessed using NGA 
particles, in which the Lipo was incorporated with chitosan 
during NGA formulation (NGA-Lipo). This increased the 
aggregation of the particles, but was less detrimental to the 
cells than the cores. Moreover, RNA was again delivered into 
DC vesicular structures. Such effects were only observed 
when Lipo was added with the chitosan during incorporation 
of RNA into the particles. If the Lipo were added with the RNA 
rather than chitosan, or together with alginate during coating, 
it had no influence; nor did admixing preformed NGA carrying 
RepRNA with Lipo.
Further analyses employing both MoDC and CD172a-
sorted blood cells—CD172ahi cells (dominated by mono-
cytes) and CD172lo cells (majority of DCs)26,27—uncovered 
differences in RepRNA and oligoRNA delivery. The latter 
preferentially targeted CD172ahi cells, whereas RepRNA 
delivery associated with both CD172hi and CD172lo cells. 
It is not clear why there should be this difference, because 
cell targeting was mediated by the NGA (free RNA did not 
interact discernibly with DCs or monocytes). Differences in 
recycling within the cells of delivered oligoRNA and RepRNA 
might be an explanation. If the CD172ahi cells initially inter-
acted more efficiently with NGA before the CD172lo cells, a 
different recycling for RepRNA could explain their increased 
appearance in CD172lo cells. It is possible that the monocytes 
were retaining both forms of RNA, whereas the DCs showed 
higher capacity for retaining the RepRNA. With the DCs being 
the more efficient antigen-presenting cell, and tending more 
to retain material, such characteristics of RepRNA delivery 
could prove beneficial for translation. Indeed, the RepRNA+ 
signal, but not oligoRNA+ signal, increased with time. This is 
also consequential for the important differences in the mode 
and intracellular sites of function for RepRNA and oligoRNA 
such as siRNA. RepRNA has an obligate requirement to 
interact with the ribosomal translation machinery; oligoRNA 
would interact with RNA-detecting entities such as TLR3/7 
and helicases or the RNA interference pathway components 
(for siRNA). Clearly, it cannot be assumed that effective 
delivery of oligoRNA such as siRNA will be reproduced with 
RepRNA delivery—these different forms of RNA have their 
own particular requirements and specialized cell compart-
ments for appropriate interaction leading to functionality.
Preliminary studies on RNA association with the NGA par-
ticles had provided a recommended dosage of 0.2 μg–0.4 
μg/ml RNA (2–4 μg RNA plus 250 μl 0.1% w/v chitosan, in 
1 ml, diluted 1:10) to ensure stability (P Käuper and Medipol 
SA, personal communication). However, this yielded variable 
results for RNA delivery when assessed with different prepa-
rations of DCs. Deviation in the functional characteristics of 
different DC isolations, from the same or different donors, may 
have contributed to these variations. Nevertheless, low con-
centration RNA cargoes did facilitate detection of enhanced 
delivery by NGA-Lipo particles. The lower dHZ and PDI of 
NGA-Lipo carrying RepRNA may have had an influence—
this was not due to free Lipo, which showed higher dHZ and 
positive ζ-potential. DCs do prefer smaller particles,39–41 and 
the surface charge of particles can also influence interaction 
with DCs.39 These studies identified another important con-
tributory factor, which was the amount of RepRNA delivered 
by NGA. Analyses on increasing the amounts of RepRNA 
cargo demonstrated that stable NGA particles with their 
cargo could be generated. Under these conditions, 4 μg/ml 
RNA was optimal for observing delivery to the cells (and 
indeed translation therein), whereby the NGA-Lipo no longer 
offered observable advantages.
Following delivery, it was essential that DCs internalized 
RepRNA. Labeling CD172a to define the DC surface con-
firmed that NGA-delivered RepRNA (and oligoRNA) was 
internalized, in a time- and temperature-dependent manner. 
RepRNA accumulated in brightly stained vesicular structures, 
typical of endocytic elements such as macropinosomes.1–4,42 
As time progressed, the appearance of an additional 
weaker RepRNA signal adjacent to these bright struc-
tures—particularly notable using NGA-Lipo with 0.2 μg/ml 
RNA cargo—was suggestive of cytosolic translocation, as 
reported for oligoRNA delivery to Hela cells.28,29 Although 
these authors did not study DCs or replicons, they described 
a similar accumulation in vesicular compartments over time. 
Adjacent weaker signals were confirmed to indicate cytosolic 
translocation.
For RepRNA, observable cytosolic translocation alone 
is inadequate. The translocation must lead to RepRNA 
 translation—this contrasts with siRNA, which must interact 
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with different intracellular compartments involved in RNA 
interference. Not surprisingly, the VRP-positive controls were 
the most effective at promoting translation. VRPs possess 
the same envelope as the virus, and therefore mimic virus 
infection; the efficiency comes from VRPs using the same 
cell receptors and efficient mechanism for cytosolic genome 
delivery as the virus.43 The need for VRPs can be seen by the 
incapacity of free RepRNA to interact with or translate in DCs. 
This fits with the RNase sensitivity of the replicon, and the 
difficulties that RNA has for crossing cell membranes.13,33,35 
Synthetic delivery vehicles were not expected to provide this 
same efficiency—they lack the VRP capacity for interacting 
with cell receptors promoting the viral cytosolic transloca-
tion mechanism. Nevertheless, NGA and NGA-Lipo delivery, 
as well as chitosan cores, did promote translation in DCs. 
Translation by NGA delivered RepRNA was not observed 
until after 24 hours, whereas NGA-Lipo and chitosan core 
delivered RepRNA showed an initial kinetics of translation 
beginning by 2 hours and increasing over 24 hours. This was 
tested using the lower 0.2 μg RNA/ml with which NGA-Lipo-
enhanced delivery was observable. It was interesting that the 
difference in translation kinetics between NGA delivery and 
NGA-Lipo delivery related to differences observed in micro-
scopic detection of the weak signals indicative of cytosolic 
translocation. Importantly, the translation was maintained 
over the 96-hour period of observation, which reflects repli-
cation of the replicon (Suter et al, unpublished data).
This successful NGA delivery of RepRNA to DCs leading to 
translation was confirmed in vivo. Again, naked RepRNA was 
incapable of translating, and therefore, no immune response 
against the encoded antigens could be induced. Considering 
the delivery vehicles, it was interesting that chitosan cores 
were as efficient as the NGA for delivery RepRNA for transla-
tion in vivo. In addition, NGA-Lipo delivery did not display the 
same capacity for enhancement over NGA delivery observed 
in vitro. This may reflect a question of detectability with the 
in vitro observations—the lower 0.2 μg RNA/ml payload was 
employed in vivo, for relating to the NGA-Lipo-enhanced 
delivery observable in vitro. Nevertheless, the in vitro transla-
tion studies had demonstrated that the increased efficiency 
of delivery by NGA-Lipo was reflected in a more rapid trans-
lation, and the NGA delivered RepRNA did eventually trans-
late to the same levels as the NGA-Lipo-delivered material 
(and also the chitosan core delivered RepRNA). It therefore 
seems likely that all three forms of the delivery vehicle were 
efficient at delivering the RepRNA for translation. Although 
there was a difference in the initial kinetics of translation, the 
production of the encoded antigens reached similar immuno-
genic levels, as witnessed by the in vivo readout.
To date, synthetic particle delivery of RNA has focused on 
siRNA and mRNA. There are no reports describing RepRNA 
interaction with DCs. Our present work characterized for the 
first time chitosan-based nanoparticulate vehicle delivery of 
self-amplifying RepRNA to DCs, promoting RepRNA trans-
lation in vitro and in vivo. The RNase-sensitive RepRNA is 
protected by the delivery vehicle, which in turn promotes 
intracellular delivery to the DCs, thus overcoming the inability 
of “naked” RepRNA to survive in biological environments and 
cross the cell membrane barrier. We are currently defining 
how targeting different DC receptors influences the efficiency 
of this delivery by synthetic, biodegradable nanoparticulate 
vehicles, relating to the endocytic processes and cytosolic 
translocation of the RepRNA for successful translation.
Materials and methods
Chemicals. Crustacean shell-origin Chitosan (low-viscosity 
chitosan, Primex, Siglufjordur, Iceland) was kindly provided 
purified through steps of acidic dissolution, 0.1 μm filtration, 
precipitation and dialysis by Medipol (Medipol SA, Lausanne, 
Switzerland). Pentasodium triphosphate, purum p.a. > 98% 
(TPP) was purchased from Sigma-Aldrich (Steinheim, Ger-
many). Sodium alginate (Na-alg, Keltone LVCR, ISP, San 
Diego, CA) was kindly provided purified by Medipol SA. 
RNAse-free water was purchased from Ambion (Life Tech-
nologies Europe B.V., Zug, Switzerland). The chitosans as 
well as 0.1% (w/v) solutions of TPP and 0.1% (w/v) solutions 
of Na-alg were prepared under sterile conditions, then ster-
ile filtered through hydrophilic membranes (0.2 μm, Minisart 
type,  Sartorius AG, Gottingen, Germany). A batch of the 
chitosan was fluorescently labeled (1:50) with carboxyrho-
damine (5(6) carboxytetramethyrhodamine, Fluka, Buchs, 
 Switzerland) using standard carbodiimide conjugation.
Self-replicating RepRNA constructs. The self-replicating 
RepRNA is derived from full-length cDNA clone pA187-1 
(ref. 44) from the noncytopathogenic classical swine fever 
virus. The cDNA was engineered to lack genes encoding viral 
structural proteins, but carrying NotI endonuclease restric-
tion sites facilitating introduction of foreign genes of inter-
est.22,24
 We have generated RepRNA-encoding luciferase,22 
as well as the HA and NP proteins of influenza virus using the 
same techniques. The constructs used on the present work 
are shown in Figure 1a, with the full classical swine fever 
virus genomic sequence for comparison. These are derived 
from cDNA clones using the published sequences of the full-
length cDNA clone pA187-1 (ref. 14,44). Viral cDNA lacking 
the Erns gene is used for the replicon (Figure 1); bicistronic 
viral cDNA is used. The first cistron contains the Npro gene 
fused in frame to the foreign gene (e.g., influenza virus NP or 
HA gene) followed by the encephalomyocarditis virus internal 
ribosomal entry site (EMCV IRES) that initiates translation 
of the remaining viral polyprotein (C to NS5B).14,22 From this 
replicon, both Npro and the foreign gene are expressed in their 
authentic form. The activities of Npro, autoprotease and inhibi-
tion of type 1 IFN induction or production, are maintained.
For generating the RepRNA packaged into viral particles 
(VRPs), the defective replicon genomes are electroporated into 
5 × 106 SK-6 cells expressing Erns (SK6 (Erns)) (refs. 22, 24). 
Following incubation at 37 °C for 48 hours, the VRPs pro-
duced are harvested by freezing and thawing of the cultures. 
The titer of VRPs is measured by infecting SK-6 cells with 
different dilutions of the VRP preparation, removing the inoc-
ulum after 1 hour, culturing for 48 hours at 37 °C, and the 
number of cells expressing the RepRNA-encoded antigens 
enumerated.
Nanogel preparation. Chitosan-TPP nanogel cores (“chitosan 
cores”) were prepared by the ionic gelation of low-viscous 
Molecular Therapy—Nucleic Acids
RepRNA and DCs
McCullough et al.
14
chitosan with TPP, according to Calvo et al. Briefly, one vol-
ume of 0.1% (w/v) TPP was added drop-wise under constant 
stirring into nine volumes of 0.1% (w/v) chitosan (e.g., 100 μl 
+ 900 μl), resulting in spontaneous chitosan-gel formation. 
The pH was maintained under pH 4 by adding 0.1 N HCl, and 
the particles thus obtained were stirred for at least 1 hour.
Empty or RNA-loaded chitosan cores (see below) were 
diluted 1:1 with RNAse-free water, then added drop-wise 
to an equal volume of 0.15% (w/v) aqueous Na-alg solution 
under strong agitation. The pH was closely monitored and 
adjusted to pH 7.0–7.3 with 0.1 mol/l NaOH to generate the 
final nanogel product. Formulations were stirred for at least 1 
hour; then stored at 4 °C overnight prior to use.
RNA encapsulation into chitosan particles. For oligoRNA-
loaded particles, either oligoRNA-Alexa488 (Qiagen AllStars 
NegsiRNA AF488, Hombrechtikon, Switzerland) or Dy781-
O1-RNA (Microsynth, Balgach, Switzerland) were added to 
the TPP solution prior to nanogel formation. The oligoRNA-
Alexa488 was dissolved at 25 pmol/ml in the 0.1% (w/v) TPP 
solution and the Dy781-O1-RNA at 120 pmol/ml. The process 
of RNA/TPP solution addition to the chitosan was held under 
the same conditions as described above, with the ratios as 
(for example) 16 μl plus 34 μl TPP added to 450 μl chitosan, 
followed by 500 μl H2O.
For RepRNA-loaded particles, either RepRNA labeled with 
fluorescein or rhodamine Mirus labeling kits (LabForce AG, 
Nunningen, Switzerland) or RepRNA labeled by incorporat-
ing Dy490-UTP (Dyomics GMBH, Jena, Germany) during 
synthesis were employed. Studies on the translation of the 
RepRNA after nanogel delivery employed unlabeled RepRNA 
to ensure that the labeling had no influence on RepRNA trans-
lation efficiency. The various forms of the RepRNA were added 
to the TPP solution prior to nanogel formation, similar to that 
described for the oligoRNA above (e.g., 2 μg RepRNA in 16 
μl plus 34 μl TPP added to 450 μl chitosan, followed by 500 μl 
H2O). The quantity of RepRNA added to the chitosan allowed 
for a concentration of 2 μg RepRNA per ml of the final NGA 
preparation prior to the 1:10 dilution for adding to the cells 
(unless otherwise stated in the Results section).
Modified nanogel preparation and RNA encapsulation. When 
particles carrying Lipofectamine 2000 (Life Technologies) 
were to be prepared (NGA-Lipo), the above method for nano-
gel preparation was employed, except that the lipofectamine 
was mixed with the chitosan prior to addition of the TPP (e.g., 
50 μl TPP added to 434 μl chitosan plus 16 μl lipofectamine). 
When RNA was incorporated, this was again applied with the 
TPP (e.g., 16 μl RepRNA + 34 μl TPP added to 450 μl chito-
san/Lipo (434 μl chitosan + 16 μl Lipofectamine).
Nanogel characterization. Hydrodynamic diameter (Z-aver-
age size, Z(av) or dHZ), PDI and surface charge (ζ-potential) 
of the particles were analyzed by dynamic light scattering 
using a Malvern ZetaSizer (ZEN3600 Nano-ZS; Malvern 
Instruments, Worcestershire, UK). Measurements were per-
formed at 25 °C at a scattering angle of 173° (see Results).45
Cell culture. Unless specified, all cell culture reagents were 
purchased from Gibco-BRL (Invitrogen, Life Technologies, 
Basel, Switzerland). South American Origin fetal bovine 
serum was acquired from Biowest (TecoMedical,  Sissach, 
Switzerland) and porcine serum from Milan Analytica 
 (Rheinfelden, Switzerland) or (Sigma-Aldrich, Buchs, Swit-
zerland). RPMI 1640, Optimem, Trypsin, 0.05% (w/v) ethyl-
enediaminetetraacetic acid (EDTA) 1× were obtained from 
Invitrogen (Life Technologies Europe B.V)
Swine kidney SK-6 cells, for producing the VRPs, were kindly 
provided by Professor Maurice Pensaert (University of Gent, 
Belgium). They were also used as the reference point for con-
trolling RepRNA replication and translation, due to their high 
capacity for accommodating both virus and replicon. These 
cells were cultured in minimum essential medium supple-
mented with glutamax and 10% (v(/v) horse serum.
Use of animals. All animal studies have been approved by the 
institute review board and performed under license from the 
competent cantonal (Canton Bern, Switzerland) and Swiss 
Federal authorities (license BE 72/12).
Generation of DCs. Porcine DCs were employed for their 
close relationship with human DCs and availability of large 
quantities from the same individual, facilitating the level 
of analyses pursued in the described experiments under 
Results. MoDCs were obtained from porcine peripheral 
blood mononuclear cells (PBMC)46 as previously described.47 
Briefly, PBMCs were isolated by density centrifugation on 
Ficoll-Paque PLUS (GE Healthcare, Glattbrugg, Switzerland), 
and monocytes were enriched from the PBMCs by magnetic 
cell sorting using the magnetic-activated cell-sorting system 
(MiltenyiBiotec, Bergisch Gladbach, Germany) and an anti-
CD172a mAb (74-22-15, kindly provided by Dr J.K. Lunney, 
US Department of Agriculture, Beltsville, MD). MoDCs were 
generated by culturing for 5 days at 39 °C in DMEM supple-
mented with 10% (v/v) porcine serum, glutamax and recom-
binant porcine granulocyte macrophage colony stimulating 
factor (150 ng/ml) plus rpIL-4 (100 U/ml); 39 °C is employed 
rather than 37 °C due to the natural body temperature of the 
pig. MoDCs were fed with fresh medium and cytokines on 
day 2 and collected for use on day 5.
Fresh blood-derived DCs were also employed. CD172alow 
cDCs+pDCs and CD172ahigh monocytes were isolated using 
magnetic-activated cell-sorting (Miltenyi Biotec) separation 
of porcine PBMCs.47 1 × 106cells/ml were cultured in DMEM 
supplemented with 1% v/v porcine serum and 50 U/ml por-
cine GM-CSF, again at 39 °C due to the natural body tem-
perature of the pig.48 The animal experiment was approved 
(authorization N° 18/04 delivered by the canton Bern) and 
carried out in accordance with the laws on care and use of 
laboratory animals in Switzerland.
A total of 10 blood donor animals were employed. The 
use of pigs allowed cells to be obtained at regular intervals 
from each individual. This permitted the identification of vari-
ability in responsiveness of the cells in terms of interaction 
with the particles and internalization of the RepRNA when 
DCs were obtained from the same individual. Such variation 
did not alter the overall interpretation of the data, and was 
actually not different from the variation observed with cells 
derived from the different blood donors. These observations 
provided a greater confidence in the results and their value 
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to the understanding of DC interactions with particles and the 
synthetic delivery of RepRNA.
RNase resistance assay. For the assay of RNase protection 
by chitosan, the procedure was as described by Python et al.49 
A 50-mer RNA oligonucleotide probe complementary to 
nucleotides 12242–12193 of the vA187-1 genome sequence 
(GenBank accession number X87939.1) and carrying a Dyo-
mics 781 modification at the 5′ end (Dy781-O1-RNA) was 
synthesized by Dr Fabian Axthelm (Microsynth AG, Balgach, 
Switzerland). The Dy781-O1-RNA probe was mixed at 40 
nmol/l final concentration with minimum essential medium 
containing 3 × 10−5 to 3 × 10−8 U RNase A/ml as digestion con-
trol, with 50 mmol/l TrisHCl pH 7.4 as negative control, and 
with the chitosan or TPP samples to be tested for RNase 
activity; all were incubated for 1 hour at 37 °C. The treated 
probes were mixed with 2 volumes of 97% Formamide 
(Sigma-Aldrich) and separated on a 10% (w/v) polyacryl-
amide and 35% (w/v) urea gel in 133 mmol/l TrisHCl, 45.5 
mmol/l boric acid, and 3.2 mmol/l EDTA. Image acquisition 
was performed with the Odyssey Infrared Imaging System 
(LI-COR, Bad Homburg, Germany).
An alternative assay used the RNaseAlert Kit (Ambion, Life 
Technologies, LuBio Science, Lucerne, Switzerland), follow-
ing the manufacturer’s instructions. The labeled RNA probe 
for detecting RNase was again associated with either chito-
san or TPP, in water or Tris buffer, as mentioned in the above 
RNase assay.
RNA upload efficacy in particles. In order to verify the effec-
tive RNA loading in particles, samples obtained from mix-
ing Dy781-O1-RNA with water (or TPP) or Dy781-O1-RNA 
incorporated into particles were distributed on Ultrafree Bio-
max 100 kDa centrifugal devices (Biomax Millipore, Fischer, 
Switzerland) and centrifuged at 1,000 ×g for 40 minutes. TPP 
or water were also added to the filters after centrifugation to 
resuspend the original samples and recover any Dy781-O1-
RNA remaining on the filters. The samples obtained before 
and after centrifugation were finally analyzed on urea page 
10% gels (100V/1 hour) and observed for infrared signaling 
analyzed with an Odyssey Scan (Li-COR).
Infrared imaging assay for nanogel delivery of Dy781-O1-
RNA. At 16 hours before nanofection, cells were seeded at 
a density of 100,000 cells/well in 96-well plates. Dy781-O1-
RNA alone or incorporated into particles were added to the 
cells and incubated at 37 °C (cell lines) or 39 °C (MoDCs) 
for the times shown in Results, then washed three times 
with cold phosphate-buffered saline (PBS)/EDTA and finally 
lysed with RA1 Lysis Buffer 1× (Macherey Nagel, Oensingen, 
 Switzerland) on ice. Controls employed Dy781-O1-RNA elec-
troporated or lipofected (Lipofectamine 2000) into the cells. 
The cells were observed for infrared signaling with an Odys-
sey Scan (LI-COR) before and after lysis.
Nanofection of cells determined by flow cytometry. Cells were 
seeded overnight at a density of 200,000 cells/well in 24-well 
or 12-well plates (Nunc, Wiesbaden, Germany) in phenol 
red-free DMEM. Alexa488-oligoRNA, Dy490-labeled RepRNA 
or fluorescein-labeled RepRNA encapsulated in particles, or 
RNA alone, were added to the cells, and incubated at 37 °C 
(cell lines) or 39 °C (MoDCs; relating to the body temperature 
of the pig donors) for various periods of times as shown in 
the results; controls employed electroporation and lipofec-
tion (Lipofectamine 2000) of the same RNA. After incubation, 
the cells were washed three times with cold PBS/EDTA, and 
their surface CD172a molecules labeled with mAb 74-22-15 
followed by the appropriate conjugate as shown in Results. 
Following a final wash, the cells were fixed with 4% (w/v) 
paraformaldehyde (PFA, Sigma-Aldrich) prior to measure-
ment on a FACS Calibur analytical FCM (Becton Dickinson, 
Basel, Switzerland) with CellQuest Pro software (Becton 
Dickinson). Analyses employed FlowJo versions 9 and 10 
software (Treestar, San Carlos, CA).
Nanofection of cells determined by confocal microscopy. 
Cells were seeded overnight at a density of 200,000 cells/
well in fibronectin-coated Lab-Tek II (Nunc) in phenol red-
free DMEM, then RNA-loaded particles (Alexa488-labeled 
oligoRNA, Dy490-labeled RepRNA, rhodamine-labeled 
RepRNA) were added to the cells and incubated at 37 °C (cell 
lines) or 39 °C (MoDCs) during 2 or 24 hours. After incuba-
tion, the cells were washed three times with cold PBS/EDTA, 
fixed with 4%(w/v) PFA and mounted in Mowiol mounting 
solution. The slides were observed by using a Leica DMRXA 
TCS-SL spectral confocal microscope and Leica LCS soft-
ware (Leica Microsystems AG, Heerbrugg, Switzerland).
MoDCs or freshly isolated blood DCs were seeded over-
night (0.2 million cells/well) in 8-well fibronectin-coated Lab-
Tek II chambers (Nunc) containing 10% v/v porcine serum 
and 50 U/ml of porcine GM-CSF (porcine experiments). 
For two-color analysis, cells were incubated with primary 
antibody against CD172a (74-22-15) for 20 minutes on ice. 
Then they were fixed with 4% (w/v) PFA for 10 minutes and 
incubated with secondary conjugated antibodies (Alexa546 or 
Alexa633; Molecular Probes, Leiden, Netherlands) in PBS for 
20 minutes. After washing twice in PBS, slides were mounted 
in Mowiol and analyzed by confocal microscopy.
Confocal microscopy employed a Leica TCS-SL confocal 
microscope and software (Leica Microsystems AG, Glattbrugg, 
Switzerland). All images were acquired using a 63× oil-immer-
sion objective, with settings to give high-resolution images 
acquired at optimum voxel size and automatic threshold 
applied. The images were analyzed using Imaris 7.5 and 7.6 
software (Bitplane AG, Zurich, Switzerland); background sub-
traction, threshold applications, gamma correction, and max-
ima settings were employed to maintain a negative image in 
the negative control cells, such that no false-positive emissions 
were present. In certain images, the anti-CD172a labeling was 
employed to delineate the cells surface, for which purpose the 
surface module of the Imaris 7.6 software was applied.
Migration assay. The ability of CD172a+ cells to detect the 
presence of nanogels was assessed by nanogel-dependent 
migration of the cells. A 24-well microchemotaxis chamber 
technique was employed, consisting of transparent 3 μm fil-
ter inserts and the corresponding 24-well companion plates 
(6.5 mm Transwell with 3.0 μm Pore Polyester Membrane 
Insert, Product #3472; Corning, Basel, Switzerland). Nano-
gels were diluted to 10% (v/v) in phenol red-free DMEM, and 
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loaded into the lower compartment of the assay system. The 
3.0 μm pore membrane inserts were then added into each 
well, and the plates incubated at 39 °C for 30 minutes. Fol-
lowing this incubation step, the upper compartment of the 
filter insert was loaded with 100 μl of CD172a-sorted cells 
(prelabeled with anti-CD172a and anti-CD14 antibodies) 
resuspended in phenol red-free DMEM to have 0.5 × 106 
cells/well. The system was incubated at 39 °C for 3 hours, 
after which the filter inserts were removed from the wells. 
The remaining contents of the wells, which contained the 
migrated cells, were transferred into FACS tubes, washed 
twice with CellWash (BD Biosciences, Allschwil, Switzer-
land), and resuspended in 100 μl of CellWash. Prior to flow 
cytometric analysis as described above, 50 μl of CountBright 
solution (Invitrogen, Lubio, Switzerland) was added to each 
sample. Quantification of the migrated cells was performed 
by counting a reference of 5000 CountBright beads.
Luciferase assay. The translation of the luciferase gene 
when encoded by the RepRNA was measured using the 
assay described by Suter et al.22 for expression levels of 
luciferase. DCs to which the RepRNA had been delivered 
were washed once with PBS, lysed with Firefly Luciferase 
Assay Lysis Buffer (Biotium, Hayward, CA) at room tem-
perature for 15 minutes and stored at −70 °C. Luciferase 
activity was quantified with a Centro LB 960 luminometer 
(Berthold Technologies, Regensdorf, Switzerland) using a 
Firefly Luciferase Assay Kit (Biotium) containing D-luciferin 
as a substrate.
Assessment of nanogel delivery of RepRNA in vivo. RepRNA 
was incorporated into NGA, NGA-Lipo, or chitosan cores as 
described above and 100 μl were used per dose for vaccina-
tion of Balb/c mice and New Zealand white rabbits. Each dose 
comprised 0.2 μg in 50 μl HA-RepRNA or C-HA-C RepRNA 
plus 0.2 μg in 50 μl NP-RepRNA; mice received one dose 
for reach RepRNA mixed together, while rabbits received 
twice this dose. The nanogel vaccines were adjuvanted with 
PEGylated MALP-2 adjuvant as described.50  Animals were 
vaccinated subcutaneously at the intervals shown in the 
Results section, and bled from the tail vein (mice) or ear 
(rabbits), also at the intervals shown in the Results sec-
tion. Anti-HA and anti-NP titers were assessed by indirect 
enzyme-linked immunosorbent assay using recombinant 
HA (H5 Vietnam 2004; related to the HA gene incorporated 
into the RepRNA, which was derived from a Swiss isolate of 
highly pathogenic avian influenza virus (Suter et al., unpub-
lished data) and NP as antigen.
These same antigens were employed at 1 μg/ml concen-
tration in splenocyte restimulation assays. Splenocytes were 
prepared from the vaccinated mice 2–3 weeks after the final 
booster vaccination, using disruption through a plastic mesh 
sieve followed by lysis of the erythrocytes. The washed sple-
nocytes were resuspended to have 107 cells/ml. Following 
prelabeling with CFSE (Biolegend, Fell, Germany) to monitor 
cell division, the cells were washed to remove unincorporated 
CFSE and then seeded in RPMI 1640 supplemented with 10% 
(v/v) fetal calf serum at 1 ml/well of 24-well plates, together with 
either no antigen (unstimulated) or 1 μg/ml recombinant HA or 
NP. After incubation at 37 °C for 7 days (refeeding at 35 days 
by replacing half of the medium), the cells were harvested and 
subjected to multicolor labeling for flow cytometric analysis. 
The labeling permitted gating of CD4+ and CD8+ T-lympho-
cytes as memory (CD3+, CD44high, CD62Llow) and naive (CD3+, 
CD44low, CD62Lhigh) populations. Proliferating cells were identi-
fied by their reduced CFSE signal (CFSElow), and scored as a 
percentage of the total cells within the above gates. A similar 
estimation was made for cells upregulating CD25 expression, 
measured as MFI; a stimulation index was calculated rela-
tive to the MFI obtained with unstimulated cells (the MFI for 
unstimulated cells was therefore 1).
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